Drug intelligence / Profile preview

BL-4060

Development stage: Discontinued
Lead developer: BioLineRx
Modality: Small Molecules
Administration: Oral

Overview

BL-4060 is a small molecule drug candidate that was under development by BioLineRx for the treatment of cancer. It was licensed in 2007 from Yissum (the technology transfer company of the Hebrew University of Jerusalem) and Hadasit (the technology transfer company of Hadassah Medical Organization). The compound is described as an orally bioavailable agent that induces apoptosis in cancer cells. While initially positioned as a potential anti-cancer therapy, the development of BL-4060 was eventually discontinued or deprioritized by BioLineRx, and the drug is no longer listed in their active clinical pipeline.

Beyond the preview

Go deeper on BL-4060.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-4060.

Explore the full profile